Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 5/20 | 0.37 |
| ▸ | L3MBTL3 | Q96JM7 | 2/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.36 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.34 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
| ▸ | USP2 | O75604 | 1/20 | 0.34 |
| ▸ | TYRO3 | Q06418 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24040191 | 0.93 | OPRL1 (0.37) | TSHRL3MBTL3L3MBTL1SIGMAR1TP53 | |
| SCHEMBL18713077 | 0.86 | TSHR (0.45) | TSHRL3MBTL1SIGMAR1TP53ALDH1A1 | |
| SCHEMBL24127742 | 0.86 | L3MBTL3 (0.38) | TSHRL3MBTL3L3MBTL1SIGMAR1TP53 | |
| SCHEMBL20094630 | 0.83 | TSHR (0.38) | TSHRL3MBTL3L3MBTL1TP53ALDH1A1 | |
| SCHEMBL20962697 | 0.82 | SIGMAR1 (0.42) | TSHRSIGMAR1TP53ALDH1A1OPRM1 | |
| SCHEMBL13881902 | 0.81 | MC4R (0.36) | TSHRALDH1A1OPRM1MEN1KMT2A | |
| SCHEMBL24755103 | 0.80 | GNAI3 (0.44) | OPRM1OPRL1 | |
| SCHEMBL19356005 | 0.78 | KDM1A (0.36) | L3MBTL3L3MBTL1TP53MEN1KMT2A | |
| SCHEMBL22281038 | 0.78 | MEN1 (0.36) | L3MBTL3L3MBTL1TP53ALDH1A1OPRM1 | |
| SCHEMBL134732 | 0.77 | L3MBTL3 (0.39) | TSHRL3MBTL3L3MBTL1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10342796-B2 | Acrylanilide derivative, preparation method, and applications thereof in pharmacy | ANCUREALL PHARMACEUTICAL (SHANGHAI) CO., LTD. (CN) | 2019-07-09 | — | — | US | disclosed |
| US-20190015413-A1 | ACRYLANILIDE DERIVATIVE, PREPARATION METHOD, AND APPLICATIONS THEREOF IN PHARMACY | ANCUREALL PHARMACEUTICAL (SHANGHAI) CO., LTD. (CN) | 2019-01-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10342796-B2 | Acrylanilide derivative, preparation method, and applications thereof in pharmacy | EGFR, ABL1, CSNK1A1 | TSHR 2545/4885L3MBTL3 4875/4885L3MBTL1 4872/4885 |
| US-20190015413-A1 | ACRYLANILIDE DERIVATIVE, PREPARATION METHOD, AND APPLICATIONS THEREOF IN PHARMACY | EGFR, ABL1, CSNK1A1 | TSHR 2545/4885L3MBTL3 4875/4885L3MBTL1 4872/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.